Art. -Nr.: HY-B0581

Dexrazoxane

(Synonyms: ICRF-187; ADR-529; NSC-169780)

19 Cited Publications

Kundenbewertung

Based on 19 publication(s) in Google Scholar

Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.88%
CAS. Nr.: 24584-09-6
Formel: C₁₁H₁₆N₄O₄
Molecular Weight:268.27

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Dexrazoxane Chemical Structure

CAS. Nr.: 24584-09-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (19)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	18 μM Compound: DEX; ICRF-187	Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay	[PMID: 33750129]

In Vitro

Dexrazoxane (0-500 μM; 0-24 h) induces DNA breaks, ATF3 accumulation, DNA damage response and apoptosis in human fibrosarcoma cell line ^[4].
Dexrazoxane(100 µM; 72 h) inhibits ferroptosis of H9c2 cells by inhibiting HMGB1^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

Topoisomerase IIα-expressing HTETOP cells (HTETOP cells were derived from the human fibrosarcoma cell line HT1080 through the deletion of both endogenous topoisomerase IIα alleles and the insertion of a tetracycline-repressible topoisomerase IIα transgene)
Concentration:

100 μM
Incubation Time:

4 h
Result:

Increased the phosphorylation level of Chk1, Chk2, ATR, and ATM.

Western Blot Analysis^[4]

Cell Line:

HTETOP cells
Concentration:

0, 10,100 and 500 μM
Incubation Time:

0, 1, 4, 8 and 24 h
Result:

Increased AFT3 protein levels in a concentration-dependent and incubation time-dependent manner.

Western Blot Analysis^[4]

Cell Line:

Topoisomerase IIα-expressing HTETOP cells
Concentration:

100 μM
Incubation Time:

24 h
Result:

Increased the expression level of P53.

Western Blot Analysis^[5]

Cell Line:

Doxorubicin (HY-15142) treated H9c2 cells
Concentration:

100 μM
Incubation Time:

72 h
Result:

Decreased the expression level of HMGB1 protein.

In Vivo

Dexrazoxane (8 mg/kg; Intravenous injection; 7 weeks) plays a protective role in rat models of cardiomyopathy induced by doxorubicin (HY-15142)^[2].
Dexrazoxane (5-15 mg/kg; Intraperitoneal injection; 3-5 weeks) has antioxidant and anti-inflammatory effects in rodent models of Parkinson's disease^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Doxorubicin (HY-15142) treated Wistar rats aged 11 weeks old^[2]
Dosage:

8 mg/kg
Administration:

Intravenous injection (i.v.); weekly for 7 weeks
Result:

Reversed the respiratory or hepatic pathology caused by doxorubicin.
Enhanced cytochrome c-oxidase activity.
Decreased myocardial ROS levels.
Reversed the mitochondrial DNA deletion caused by doxorubicin.

Animal Model:

6-OHDA (HY-B1081) treated Sprague Dawley rats (180-220 g);
MPTP ( HY-15608 ) and probenecid (HY-B0545) treated mice aged 10 weeks old^[6]
Dosage:

5 and 15 mg/kg;
10 mg/kg
Administration:

Intraperitoneal injection (i.p.); 3 weeks
Intraperitoneal injection (i.p.); 5 weeks
Result:

Attenuated neurotoxin-induced oxidative damage in serum, midbrain and striatum.
Suppressed neurotoxin-induced systemic inflammation in both of serum and midbrain.
Ameliorated neurotoxin-induced ER stress in midbrain.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 24584-09-6
Appearance Solid
Molecular Weight 268.27
Formel C₁₁H₁₆N₄O₄
Color White to light yellow
SMILES

C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
Synonyms

ICRF-187; ADR-529; NSC-169780
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (19)

All Bio/Physico-chemical AssayFlow CytometryCell Imaging/StainingRT-PCRIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Med

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. [Abstract]

2016 May;22(5):547-56. PMID: 27089514
Adv Sci (Weinh)

The Imbalance of p53-Park7 Signaling Axis Induces Iron Homeostasis Dysfunction in Doxorubicin-Challenged Cardiomyocytes. [Abstract]

2023 May;10(15):e2206007. PMID: 36967569

Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) resulted in a decline in contractile speed in NMCMs.

Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) resulted in a decline in cell viability in NMCMs.

Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) inhibited DOX-induced iron accumulation and ROS and restored mitochondrial membrane potential in NMCMs.

Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) reversed Ptgs2 mRNA expression in NMCMs.

Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (20 mg/kg; i.p.; weekly for 4 weeks) reversed the DOX-induced decrease in body weight and the ratio of heart weight to tibia length (HW/TL) of chronic DoIC (doxorubicin (DOX)-induced cardiotoxicity) mice.
Nano Res

2023 Apr 18.
J Pharm Anal

2026 Mar 10.
Phytomedicine

Quercetin ameliorates doxorubicin-induced atrial fibrillation via EGFR-mediated restoration of autophagic flux. [Abstract]

2025 Oct 3:148:157357. PMID: 41056856
Phytomedicine

20-Deoxyingenol attenuated doxorubicin-induced cardiotoxicity by promoting autolysosome degradation through the UCHL3-TFEB pathway. [Abstract]

2025 Nov:147:157220. PMID: 40916238
Phytomedicine

Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway. [Abstract]

2023 Aug:117:154922. PMID: 37321078
Free Radic Biol Med

Crucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury. [Abstract]

2024 Dec 9:227:296-311. PMID: 39653130
Free Radic Biol Med

Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. [Abstract]

2020 Nov 20;160:303-318. PMID: 32846217
Br J Pharmacol

Targeting FDX1 by trilobatin to inhibit cuproptosis in doxorubicin-induced cardiotoxicity. [Abstract]

2025 Jun;182(11):2409-2425. PMID: 39933533
Biomed Pharmacother

ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. [Abstract]

2022 Sep:153:113280. PMID: 35724508
Eur J Med Chem

Praeruptorin A screened by a ferrous ion probe inhibited DMT1 and ferroptosis to attenuate Doxorubicin-induced cardiomyopathy. [Abstract]

2024 Nov 26:283:117108. PMID: 39615370
Biochem Pharmacol

Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway. [Abstract]

2024 Jun:224:116247. PMID: 38697311
J Ethnopharmacol

Huanglian-ejiao decoction ameliorates doxorubicin-induced cardiomyocyte apoptosis and autophagic flux dysregulation by up-regulating ubiquilin1. [Abstract]

2025 Oct 14:120751. PMID: 41101550
J Cell Mol Med

Downregulation of Alox5 Inhibits Ferroptosis to Improve Doxorubicin-Induced Cardiotoxicity via the P53/SLC7A11 Pathway. [Abstract]

2025 Jun;29(11):e70641. PMID: 40485049
Environ Toxicol Pharmacol

Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. [Abstract]

2023 Oct:103:104261. PMID: 37689219
Cardiovasc Toxicol

Marein Alleviates Doxorubicin-Induced Cardiotoxicity through FAK/AKT Pathway Modulation while Potentiating its Anticancer Activity. [Abstract]

2024 Aug;24(8):818-835. PMID: 38896162
Mol Med Rep

Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress. [Abstract]

2024 May;29(5):84. PMID: 38516760
Biochem Biophys Res Commun

The m6A modification reader protein IGF2BP2 regulates ferroptosis in nasopharyngeal carcinoma cells by stabilizing CP expression via an m6A-dependent mechanism. [Abstract]

2025 Sep 8:778:152417. PMID: 40743989

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (93.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7276 mL

18.6379 mL

37.2759 mL

5 mM

0.7455 mL

3.7276 mL

7.4552 mL

10 mM

0.3728 mL

1.8638 mL

3.7276 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 6.67 mg/mL (24.86 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rahimi P, et al. Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines. Cureus. 2023 Apr 8;15(4):e37308. [Content Brief]

[2]. Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007 Jul;151(6):771-8. [Content Brief]

[3]. de Baat EC, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022 Dec;6(12):885-894. [Content Brief]

[4]. Deng S, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172(9):2246-57. [Content Brief]

[5]. Zhang H, et al. Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021 Jul 14;8:685434. doi: 10.3389/fcvm.2021.685434. [Content Brief]

[6]. Mei M, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1;160:107758. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7276 mL	18.6379 mL	37.2759 mL	93.1897 mL
	5 mM	0.7455 mL	3.7276 mL	7.4552 mL	18.6379 mL
	10 mM	0.3728 mL	1.8638 mL	3.7276 mL	9.3190 mL
	15 mM	0.2485 mL	1.2425 mL	2.4851 mL	6.2126 mL
	20 mM	0.1864 mL	0.9319 mL	1.8638 mL	4.6595 mL
	25 mM	0.1491 mL	0.7455 mL	1.4910 mL	3.7276 mL
	30 mM	0.1243 mL	0.6213 mL	1.2425 mL	3.1063 mL
	40 mM	0.0932 mL	0.4659 mL	0.9319 mL	2.3297 mL
	50 mM	0.0746 mL	0.3728 mL	0.7455 mL	1.8638 mL
	60 mM	0.0621 mL	0.3106 mL	0.6213 mL	1.5532 mL
	80 mM	0.0466 mL	0.2330 mL	0.4659 mL	1.1649 mL

Dexrazoxane

19 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dexrazoxane

Apoptosis Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Dexrazoxane

Biologische Aktivität

Chemical Information

Publications (19)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dexrazoxane Related Classifications

Art. -Nr.: HY-B0581